Previous 10 | Next 10 |
Six multi-billion dollar deals announced last week. VICI Properties acquires MGM Growth Properties for $17.2 billion. Veoneer receives a superior bid from Qualcomm. For further details see: Merger Arbitrage Mondays - Veoneer Receives A Superior Bid From Qualcomm
Gainers: Profound Medical (NASDAQ:PROF) +28%, STAAR Surgical (NASDAQ:STAA) +19%, AdaptHealth (NASDAQ:AHCO) +17%, Flora Growth (NASDAQ:FLGC) +16%, Invacare (NYSE:IVC) +15%. Losers: Inogen (NASDAQ:INGN) -32%, Karyopharm Therapeutics (NASDAQ:KPTI) ...
Fastly FSLY -23% on Q2 earnings release Karyopharm Therapeutics KPTI -18% on Q2 earnings release Fiverr International FVRR -17% on Q2 earnings release Etsy ETSY -13% on Q2 earnings release Maxar Technologies MAXR -13% on Q2 earning...
Xeris Pharmaceuticals (NASDAQ:XERS): Q2 GAAP EPS of -$0.41 misses by $0.14. Revenue of $8.84M (+346.5% Y/Y) misses by $4.95M. Press Release For further details see: Xeris Pharmaceuticals EPS misses by $0.14, misses on revenue
Gvoke® prescription volume up 32% versus prior quarter Gvoke unit sales to wholesalers and other direct customers up 36% versus prior quarter Gvoke quarterly net sales up 10% to $8.8 million versus prior quarter Strong cash position of $116 million ...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) ( Xeris ) today announced in accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the Irish Takeover Rules ) that, as of the close of business on July 28, 2021, Xeris' issued share capital, excluding tre...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that the Company will release its second quarter 2021 financial re...
Barry Deutsch is stepping down as CFO; remains key employee through the anticipated closing of previously announced transaction Steve Pieper, VP of Finance, assumes the role of CFO Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leverag...
Xeris Pharmaceuticals (XERS) has signed an exclusive agreement with Tetris Pharma for the commercialization of Ogluo in a deal worth as much as $71M.The agreement, in the European Economic Area, United Kingdom, and Switzerland, allows for the treatment of severe hypoglycae...
Up to $71 million in time- and milestone-based payments, plus royalties on sales Agreement covers 32 countries First launch expected in Q4 2021 in UK Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulati...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...
In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate. Lower mUFC at baseline was also associated with lower maintenance dose requirements and lower rates of potentially clinically important liver-re...